Stereotactic Post-operative Radiotherapy for Endometrial Cancer
Stereotactic Post-operative Radiotherapy for Endometrial Cancer: Patients candidate to receive adjuvant radiotherapy will be assigned to a shorter schedule of 30 Gy in 5 sessions.
Study summary
The primary endpoint of the present prospective study is to assess the outcomes in terms of acute toxicity of post-operative stereotactic radiotherapy for endometrial cancer
Eligibility
Sex
FEMALE
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
* Age 18-80 years
* ECOG PS ≤ 2 or KPS ≥ 70%
* Patients diagnosed with endometrial cancer (endometrioid, serous cell, clear cell, carcinosarcoma) FIGO stage IB-IIIC1 candidate to post-operative external beam radiotherapy, based on molecular and histological findings
* Indications for chemotherapy and/or brachytherapy are not exclusion criteria for the purpose of the study
* Written Informed Consent
Exclusion Criteria:
* Prior pelvic radiotherapy
* Para-aortic lymph nodes involvement
* ECOG PS ≥ 3
* Any diagnosis of inflammatory bowel disease (both active or quiescent)
Primary outcome measure(s)
Acute G3 or higher Gastrointestinal and Genitourinary Toxicity — From the end of treatment to a time interval of 12 weeks The number of any G3 or higher adverse event occurring within 90 days from the end of radiotherapy and assessed according to the CTCAE v5.0 criteria
Trial sites (2)
Facility
City
Region
Status
ARNAS Civico Hospital
Palermo
Italy
Not Yet Recruiting
ARNAS Civico Hospital
Palermo
Italy
Recruiting
More ARNAS Civico Di Cristina Benfratelli Hospital trials in Italy
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
